News

Over the past 15 years, the cancer center’s Community Advisory Board (CAB) has become one of UCSF’s most instrumental community outreach groups for improving health equity. In a Q&A below, CAB Chair Arnold Perkins and Dr. Kim Rhoads discuss why CABs are critical to the work of NCI cancer centers and

UC San Francisco scientists have discovered a new way to control the immune system’s “natural killer” (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies

Six UC San Francisco researchers have won an Endeavor Award to build a new research collaborative at the University focused on decoding the “rulebook” of metastatic cancer as a pathway to new treatments. The Mark Foundation for Cancer Research established the awards to support research challenges

This year was difficult for all of us, personally and collectively. The COVID-19 pandemic transformed every aspect of our lives and called for us to adapt in unprecedented ways. It was gratifying – yet not surprising – to see how the UCSF community met the challenges of 2020. In cancer, our care

Byron C. Hann, MD, PhD, Research Scientist and Manager of the Preclinical Therapeutics Core at the Helen Diller Family Comprehensive Cancer Center will be retiring at the end of the month. Since his arrival in 1984, Dr. Hann has collaborated with UCSF's best and brightest scientists and helped to

The University of California’s two nationally ranked medical centers, UC San Francisco and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and